JP2023552583A5 - - Google Patents

Info

Publication number
JP2023552583A5
JP2023552583A5 JP2023535063A JP2023535063A JP2023552583A5 JP 2023552583 A5 JP2023552583 A5 JP 2023552583A5 JP 2023535063 A JP2023535063 A JP 2023535063A JP 2023535063 A JP2023535063 A JP 2023535063A JP 2023552583 A5 JP2023552583 A5 JP 2023552583A5
Authority
JP
Japan
Application number
JP2023535063A
Other languages
Japanese (ja)
Other versions
JPWO2022122914A5 (https=
JP2023552583A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/084987 external-priority patent/WO2022122914A1/en
Publication of JP2023552583A publication Critical patent/JP2023552583A/ja
Publication of JP2023552583A5 publication Critical patent/JP2023552583A5/ja
Publication of JPWO2022122914A5 publication Critical patent/JPWO2022122914A5/ja
Pending legal-status Critical Current

Links

JP2023535063A 2020-12-10 2021-12-09 置換されたピラゾロピペリジンカルボン酸類 Pending JP2023552583A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20213020 2020-12-10
EP20213020.9 2020-12-10
PCT/EP2021/084987 WO2022122914A1 (en) 2020-12-10 2021-12-09 Substituted pyrazolo piperidine carboxylic acids

Publications (3)

Publication Number Publication Date
JP2023552583A JP2023552583A (ja) 2023-12-18
JP2023552583A5 true JP2023552583A5 (https=) 2024-12-10
JPWO2022122914A5 JPWO2022122914A5 (https=) 2024-12-10

Family

ID=73793025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535063A Pending JP2023552583A (ja) 2020-12-10 2021-12-09 置換されたピラゾロピペリジンカルボン酸類

Country Status (31)

Country Link
US (1) US20240051935A1 (https=)
EP (1) EP4259617B1 (https=)
JP (1) JP2023552583A (https=)
KR (1) KR20230118144A (https=)
CN (1) CN116710439A (https=)
AR (1) AR124297A1 (https=)
AU (1) AU2021393988A1 (https=)
CA (1) CA3204495A1 (https=)
CL (1) CL2023001632A1 (https=)
CO (1) CO2023007335A2 (https=)
CR (1) CR20230242A (https=)
DK (1) DK4259617T3 (https=)
DO (1) DOP2023000115A (https=)
EC (1) ECSP23040828A (https=)
ES (1) ES2997117T3 (https=)
FI (1) FI4259617T3 (https=)
GE (2) GEAP202316287A (https=)
HR (1) HRP20241543T1 (https=)
HU (1) HUE069255T2 (https=)
IL (1) IL303296A (https=)
JO (1) JOP20230132A1 (https=)
LT (1) LT4259617T (https=)
MX (1) MX2023006903A (https=)
PE (1) PE20231501A1 (https=)
PL (1) PL4259617T3 (https=)
PT (1) PT4259617T (https=)
RS (1) RS66294B1 (https=)
SA (1) SA523441083B1 (https=)
SI (1) SI4259617T1 (https=)
TW (1) TW202237589A (https=)
WO (1) WO2022122914A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011873A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4011874A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4536205A1 (en) 2022-06-09 2025-04-16 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women
JP2026504406A (ja) * 2023-01-31 2026-02-05 インビボサイエンシーズ インコーポレイテッド 駆出率保持型心不全(HFpEF)の治療に関するシステムおよび方法
WO2025067414A1 (zh) * 2023-09-27 2025-04-03 海思科医药集团股份有限公司 吡唑羧酸衍生物及其在医药上的应用
WO2025162280A1 (zh) * 2024-01-30 2025-08-07 海思科医药集团股份有限公司 吡唑羧酸衍生物及其在医药上的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
KR20100059952A (ko) * 2007-09-06 2010-06-04 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 사이클라제 활성제
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
EA023221B1 (ru) 2010-02-27 2016-05-31 Байер Интеллектуэль Проперти Гмбх СВЯЗАННЫЕ БИС-АРИЛЬНЫЕ АРИЛ-ТРИАЗОЛОНЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО НА ИХ ОСНОВЕ И ДВОЙНОЙ АНТАГОНИСТ V1a/V2-РЕЦЕПТОРОВ
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PE20130779A1 (es) 2010-07-09 2013-06-21 Bayer Ip Gmbh Pirimidinas y triazinas condensadas y su uso
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
EP2632551B1 (en) * 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
ES2748798T3 (es) * 2012-09-07 2020-03-18 Boehringer Ingelheim Int Alcoxi pirazoles como activadores de la guanilato ciclasa soluble
WO2015095515A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
UA121558C2 (uk) 2014-11-03 2020-06-25 Баєр Фарма Актіенгезеллшафт Гідроксіалкілзаміщені фенілтриазольні похідні та їх застосування
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
JP7458683B2 (ja) * 2020-12-10 2024-04-01 バイエル・アクチエンゲゼルシヤフト 眼科疾患の治療のためのsGC活性化剤の使用
CN116829545A (zh) * 2020-12-10 2023-09-29 拜耳公司 取代的吡唑基哌啶羧酸

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)